Genzyme, the Cambridge biotechnology company now owned by French drug maker Sanofi SA, said that a drug used in treating thyroid cancer has been approved for wider use in Europe.

The drug is Thyrogen, and it has been approved for use in the management of patients with thyroid cancer in the United States since 1998. It has also been approved for use in Europe.